Overview
Truveris provides technology and data analytics for the prescription drug sector, working within the pharmacy supply chain. It serves payers, brokers, and manufacturers with insights and tools to manage pharmacy benefits more effectively. The core offering includes technology solutions and data analytics services for cost containment, clinical guidance, and strategic program design, plus patient access programs that help pharmaceutical brands reach patients and anticipate market shifts. Truveris helps clients stay ahead of regulatory changes (such as FDA recalls) and navigate evolving pharmacy rules. Its goal is to deliver clear, confident insights into pharmacy benefits to improve employee health, productivity, and satisfaction while supporting client growth with branded programs and advisory services.
Work here?Claim your company
About Truveris
Industries
Company Size
51-200
Company Stage
Series E
Total Funding
$69.1M
Headquarters
Greenville, Delaware
Founded
2009
Get referred to Truveris
See people who can refer or advise you
Simplify's Take
What believers are saying
- CAA 2026 and PBM Kickback Prohibition Act debates increase demand for Truveris oversight.
- Truveris published GLP-1 resources on May 5 and September 8, 2026 for employers.
- Leadership promotions on 2026-03-31 centralized commercial, pharmacy, and operations execution under one team.
What critics are saying
- Federal Circuit affirmed Truveris v. SkySail on April 3, 2024, weakening patent leverage.
- By 2027, PBM transparency becomes table stakes, turning Truveris into a services commodity.
- Truveris had 91 employees on July 31, 2026, limiting scale against CVS and Optum.
What makes Truveris unique
- Truveris’ March 31, 2026 Center of Excellence combines PharmDs, analytics, and PBM procurement expertise.
- Its September 19, 2024 Cost Plus Drugs collaboration reinforces independence and transparent-pharmacy positioning.
- The platform’s 100% claims analysis and RFP oversight attack opaque PBM pricing directly.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$69M
Below
Industry Average
Funded Over
6 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
1%1 year growth
1%2 year growth
0%Truveris, the leader in pharmacy cost containment and program performance, today announced it has raised $15 million in Series E investment led by two lead i...
Truveris collaborates with Mark Cuban Cost Plus Drug Company to reduce pharmacy benefits spend.
Truveris, a Wilmington, DE-based company specializing in pharmacy cost containment, raised $15M in Series E funding. The round was led by Canaan Partners and New Leaf Venture Partners. The funds will support corporate development and operational growth. CEO Nanette Oddo stated that the financing validates their solutions and growth potential, and they aim to transform and reduce pharmacy spend for employers and their plan members.
Truveris, a pharmacy cost containment and program performance company, raised $15 million in Series E funding led by Canaan Partners and New Leaf Venture Partners. The funding will support corporate development and operational growth. Truveris' platform replaces traditional pharmacy benefit manager models, providing transparency and savings. CEO Nanette Oddo highlighted the validation of their solutions and growth potential. For more information, contact [email protected].
Truveris, a Wilmington, DE-based company which specializes in pharmacy cost containment and program performance, raised $15M in Series E funding.
There are no jobs for Truveris right now.
Find jobs on Simplify and start your career today
About Truveris
Industries
Company Size
51-200
Company Stage
Series E
Total Funding
$69.1M
Headquarters
Greenville, Delaware
Founded
2009
There are no jobs for Truveris right now.
Find jobs on Simplify and start your career today